# Regulatory References for BioEq

This document provides key regulatory references relevant to bioequivalence assessments and the validation of analytical methods used in the BioEq package.

## FDA Guidance Documents

### Primary Guidance for Bioequivalence

1. **FDA Guidance for Industry: Statistical Approaches to Establishing Bioequivalence** (January 2001)  
   https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence  
   *This is the foundational document for statistical methods in bioequivalence studies. It outlines acceptable approaches for the design, conduct, and analysis of bioequivalence studies.*

2. **FDA Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs â€” General Considerations** (March 2014, Revised February 2019)  
   https://www.fda.gov/media/88254/download  
   *This guidance provides general recommendations on how to meet regulatory requirements for bioavailability and bioequivalence in investigational new drug applications (INDs), new drug applications (NDAs), and their supplements.*

3. **FDA Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA** (December 2013)  
   https://www.fda.gov/media/87219/download  
   *This guidance focuses on bioequivalence study design and data analysis for abbreviated new drug applications (ANDAs).*

### Software Validation and Electronic Records

4. **FDA General Principles of Software Validation; Final Guidance for Industry and FDA Staff** (January 2002)  
   https://www.fda.gov/media/73141/download  
   *This guidance outlines general validation principles that the FDA considers appropriate for the validation of software used in medical devices or pharmaceutical manufacturing.*

5. **21 CFR Part 11: Electronic Records; Electronic Signatures** (March 1997, updated)  
   https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11  
   *This regulation establishes requirements for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records.*

6. **FDA Data Standards Strategy** (most recent version)  
   https://www.fda.gov/industry/fda-data-standards-advisory-board/data-standards-strategy  
   *This strategy document outlines FDA's approach to data standards and their importance in regulatory submissions.*

## European Medicines Agency (EMA) Guidelines

7. **EMA Guideline on the Investigation of Bioequivalence** (January 2010)  
   https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf  
   *This guideline provides detailed information on the design, conduct, and evaluation of bioequivalence studies for immediate release dosage forms with systemic action.*

8. **EMA Guideline on Missing Data in Confirmatory Clinical Trials** (July 2010)  
   https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-missing-data-confirmatory-clinical-trials_en.pdf  
   *This guideline addresses methods for handling missing data in clinical trials.*

## International Council for Harmonisation (ICH) Guidelines

9. **ICH E9: Statistical Principles for Clinical Trials** (February 1998)  
   https://database.ich.org/sites/default/files/E9_Guideline.pdf  
   *This guideline provides statistical principles to be considered in the design, conduct, analysis, and evaluation of clinical trials.*

10. **ICH E6(R2): Good Clinical Practice** (November 2016)  
    https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf  
    *This guideline provides an international ethical and scientific quality standard for the design, conduct, recording, and reporting of clinical trials.*

## GAMP Guidelines

11. **GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems** (2008)  
    International Society for Pharmaceutical Engineering (ISPE)  
    *This is a key industry standard for validation of computerized systems in regulated environments.*

## Standards Organizations

12. **ANSI/ASQ Z1.4: Sampling Procedures and Tables for Inspection by Attributes** (2013)  
    American National Standards Institute/American Society for Quality  
    *This standard provides sampling plans for quality inspection and testing.*

13. **ISO 5725: Accuracy (trueness and precision) of measurement methods and results** (1994, parts 1-6)  
    International Organization for Standardization  
    *This standard provides principles and methods for assessing the accuracy of measurement methods and results.*

## Software Validation Resources

14. **PIC/S Guidance: Good Practices for Computerised Systems in Regulated "GXP" Environments** (September 2007)  
    Pharmaceutical Inspection Co-operation Scheme  
    *This document provides guidance on good practices for computerized systems in GxP-regulated environments.*

15. **NIST Special Publication 500-234: Reference Information for the Software Verification and Validation Process** (1996)  
    National Institute of Standards and Technology  
    *This publication provides reference information for software verification and validation processes.*

## Statistical References

16. **Statistical Methods in Bioequivalence (RSABE):** SAS/STAT(R) 9.2 User's Guide, Second Edition - The TTEST Procedure.  
    https://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/viewer.htm#statug_ttest_sect003.htm  
    *Documentation on statistical methods used in reference-scaled average bioequivalence.*

17. **FDA Product-Specific Guidances for Generic Drug Development**  
    https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development  
    *These guidances provide specific recommendations on bioequivalence study design for individual drug products.* 